Quick Answer
InMed Pharmaceuticals Inc. reported Total Revenue of $4.94 million for fiscal year 2025.
InMed Pharmaceuticals Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $4.94M | +7.5% |
| 2024 | $4.60M | +11.2% |
| 2023 | $4.14M | +279.6% |
| 2022 | $1.09M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $820.2K | -26.2% | -26.8% |
| September 30, 2025 | $1.12M | -11.4% | -11.2% |
| March 31, 2025 | $1.26M | +7.6% | +13.5% |
| December 31, 2024 | $1.11M | -10.4% | -12.1% |
| September 30, 2024 | $1.26M | +40.2% | +7.8% |
| March 31, 2024 | $1.17M | +13.4% | -5.5% |
| December 31, 2023 | $1.24M | +164.0% | +37.5% |
| September 30, 2023 | $901.9K | +181.1% | -12.8% |
- InMed Pharmaceuticals Inc. showed an increase of +7.5% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, InMed Pharmaceuticals Inc.’s total revenue has grown by 353.7% (from $1.09 million to $4.94 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: